KAIST reprograms colon cancer cells

KAIST’s claim that colon cancer cells were “reprogrammed” into normal-like intestinal cells is real, but it is not a new result from this week and it is not, at least from the public record, a fresh paper posted on May 20. KAIST announced the work on December 20, 2024, and the study appeared in *Advanced Science* in January 2025, according to the university and the journal’s PubMed Central record. Professor Kwang-Hyun Cho’s team at the Korea Advanced Institute of Science and Technology described the approach as cancer “reversion” rather than cell killing. In KAIST’s account, the group built a computational model of normal colon-cell differentiation, then used that model to identify regulatory factors that could push colorectal cancer cells back toward a normal-like intestinal state. ### So did KAIST actually turn cancer cells into healthy cells? (news.kaist.ac.kr) The January 2025 *Advanced Science* paper says the team identified MYB, HDAC2 and FOXA2 as master regulators and that simultaneous knockdown of those regulators reverted colorectal cancer cells into “normal-like enterocytes.” The paper summary says the effect was shown by inducing differentiation and suppressing malignant features. KAIST’s December 2024 release used similar language, saying the switches were applied to colon cancer cells and that the cells “reverted to a normal-like state,” with confirmation from molecular and cellular experiments as well as animal studies. (news.kaist.ac.kr) The university did not describe this as a proven treatment in patients. ### What exactly did the researchers do? KAIST said the team started from single-cell transcriptome data tracking how normal colon cells differentiate. (pmc.ncbi.nlm.nih.gov) The researchers then built what the university called a “digital twin” of the gene network governing that trajectory and used simulations to identify control factors that drive normal colon-cell differentiation. The three factors highlighted by KAIST were HDAC2, FOXA2 and MYB. (news.kaist.ac.kr) The *Advanced Science* summary says inhibiting those regulators could induce enterocyte differentiation, which is the mature absorptive cell type lining the intestine. ### What evidence is public, and what is still missing? PubMed Central’s record confirms the paper exists, names the authors, and says the work was published in *Advanced Science* on January 20, 2025. (news.kaist.ac.kr) That directly undercuts the impression from recent social posts that the claim surfaced without a paper trail. The social-media description about restored morphology, gene-expression profiles matching non-cancerous tissue, and normal absorptive function is directionally consistent with the paper’s “normal-like enterocyte” framing, but those specific assay details were not fully visible in the records reviewed here. (news.kaist.ac.kr) What is clearly documented is the gene set, the computational framework, and the claim that the effect was validated in vitro and in vivo. (pmc.ncbi.nlm.nih.gov) ### Why are scientists calling this “reversion” instead of treatment? KAIST and Cho’s group have been developing “cancer reversion” as a research program for several years. A 2023 *Advanced Science* paper from Cho and co-authors argued that cancer networks can, in principle, be normalized rather than only destroyed, and a February 2025 KAIST release described a related framework for identifying a molecular switch at a critical transition in colorectal tumorigenesis. (pmc.ncbi.nlm.nih.gov) A 2024 review co-authored by Dongkwan Shin and Kwang-Hyun Cho said true cancer reversion in solid tumors remains challenging and depends on showing durable movement to a nonmalignant state. That is the standard this line of work is trying to meet. ### What should readers take from the claim now? The dated public record is straightforward: KAIST announced the colon-cancer reprogramming work in December 2024, and *Advanced Science* published the study in January 2025. (pmc.ncbi.nlm.nih.gov) The reported result is a lab and animal finding centered on MYB, HDAC2 and FOXA2, not a human therapy and not a brand-new paper from May 2026. The next concrete milestone is replication outside Cho’s group and additional preclinical work showing whether the normal-like state is stable, durable and safe. (pmc.ncbi.nlm.nih.gov) KAIST’s own materials say the framework may be applied to other cancers, but the evidence cited so far remains preclinical. (news.kaist.ac.kr 1) (news.kaist.ac.kr 2)